neurology

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

News

Asarina folds as it ends search for Tourette's drug partner

The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company.

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

uniQure rockets on Huntington’s gene therapy result

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two

News

NeuroSense says ALS drug extends survival

NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes

News

Blood test could spot Parkinson’s years earlier

An artificial intelligence-powered blood test that may be able to predict Parkinson’s disease several years before symptoms start to develop could allow earlier treatment and help guide the

Lilly's tau drug for Alzheimer's flunks phase 2 test

Asarina folds as it ends search for Tourette's drug partner

Novo leads $100m financing for Alzheimer's player Asceneuron

uniQure rockets on Huntington’s gene therapy result

NeuroSense says ALS drug extends survival

Blood test could spot Parkinson’s years earlier

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

neurology

Editor's Picks